US5011471027
US5011471027
Krystal Biotech, Inc.
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 9.82B EUR | 11B EUR | 7.6B EUR | 7.2B EUR |
Enterprise Value | 8.85B EUR | 10.58B EUR | 7.11B EUR | 6.71B EUR |
Valuation Multiples | ||||
Trailing P/E | 41.56x | 45.56x | 33.79x | 42.56x |
Forward P/E | 35.78x | -- | -- | -- |
Price to Sales | 22.28x | 24.97x | 18.22x | 23.91x |
Price to Book | 7.22x | 8.09x | 5.96x | 5.9x |
EV/Revenue | 20.09x | 24.02x | 17.04x | 22.3x |
EV/EBITDA | 44.41x | 51.76x | 38.37x | 51.63x |
Price to FCF (P/FCF) | 64.68x | 42.67x | 32.03x | 43.84x |
EV/FCF | 58.33x | 41.05x | 29.96x | 40.88x |
FCF Yield | 1.55% | 2.34% | 3.12% | 2.28% |